

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1(Canceled).

2(Previously Presented). The method according to claim 32, further comprising delivering an estrogen in combination with the compound of formula I.

3(Previously Presented). The method according to claim 2, wherein the estrogen is delivered prior to or subsequent to the compound of formula I.

4-7(Canceled).

8(Previously Presented). The method according to Claim 32, wherein said compound is selected from the group consisting of 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile, 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile, or a pharmaceutically acceptable salt.

9(Previously Presented). The method according to claim 32, wherein said compound is 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, or a pharmaceutically acceptable salt.


10(Previously Presented). The method according to claim 32, wherein R¹ and R² are fused to form a carbon-based 3 to 6 membered saturated spirocyclic ring.

11-28(Canceled).

29(Previously Presented). The method according to claim 32, wherein said compound is 5-(4-ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 5-(4,4-diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazine-6-yl]-1H-pyrrole-2-carbonitrile or pharmaceutically acceptable salts thereof.

30-31(Canceled).

32(Previously Presented). A method of treating acne or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising an effective amount of a compound of formula I and a physiologically compatible carrier, wherein said compound of formula I is of the structure:



wherein:

R^1 and R^2 are independent substituents selected from the group consisting of H, C_1 to C_6 alkyl, and substituted C_1 to C_6 alkyl; or

R^1 and R^2 are fused to form a carbon-based 3 to 8 membered saturated spirocyclic ring;

R³ is H;

R⁴ is H;


R⁵ is a five membered carbon-based heterocyclic ring having in its backbone 1, 2, or 3 NR⁶ heteroatoms and having one or two independent substituents selected from the group consisting of H, halogen, and CN;

R⁶ is selected from the group consisting of H, C₁ to C₃ alkyl, and C₁ to C₄ CO₂alkyl;

Q¹ is S;

or a pharmaceutically acceptable salt.

33(Previously Presented). A method of treating acne or hirsutism in a mammal comprising administering to said mammal in need thereof a composition comprising an effective amount of a compound of formula I represented by the structure:



wherein:

R^{1'} is selected from the group consisting of methyl, ethyl, and trifluoromethyl;

R^{2'} is selected from the group consisting of methyl, ethyl, and trifluoromethyl; or

R^{1'} and R^{2'} are joined to form a spirocyclic ring containing 3 to 7 carbon atoms;

and

R^{3'} is C₁ to C₄ alkyl;

or a pharmaceutically acceptable salt thereof to treat said acne or hirsutism.

34(Currently Amended). The method according to claim 33, wherein said compound is 5-(4-ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 5-(4,4-diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,4-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1H-pyrrole-2-carbonitrile 1-

methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-(2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl)-1H-pyrrole-2-carbonitrile, 1-methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazine-6-yl]-1H-pyrrole-2-carbonitrile 1-methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazine-6-yl]-1H-pyrrole-2-carbonitrile or pharmaceutically acceptable salts thereof.

35(Previously Presented). The method according to claim 33, wherein said compound is 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, or pharmaceutically acceptable salts thereof.